Early access
Sign in
Taking people in FrancePhase 1

Tests a fludarabine PET scan in people with symptomatic multiple myeloma

Studies a fludarabine PET scan to assess multiple myeloma in adults with symptoms.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nantes
Where
Angers, Brest, Caen Cedex 9, Nantes Cedex 1, and Tours, FranceSee the 5 sites
Registry title
MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.
Status
Recruiting
Phase
Phase 1
People taking part
35 people, planned
Started
8 Nov 2024
Expected to end
7 Sept 2031
Type of study
Interventional
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with symptomatic multiple myeloma, newly diagnosed or relapsed, to study a PET scan using 18F-Fludarabine.

Age
18 years or older
Sex
Women and men can join
Disease stage
Symptomatic multiple myeloma, at first assessment or after relapse

Where in France

  • Centre Hospitalier Regional D'AngersAngers, FranceTaking people
  • Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
  • Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranceTaking people
  • Centre Hospitalier Universitaire De NantesNantes Cedex 1, FranceTaking people
  • Centre Hospitalier Régional Universitaire de ToursTours, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests a fludarabine PET scan in people with symptomatic multiple myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
15 July 2026